Redeye: Xvivo Perfusion - High Activity Ahead
Sales of consumables in Q1 were in line with our forecast, but total sales beat our estimates due to higher-than-expected sales of durable goods. We foresee a high activity in the coming 12 months, with the initiation of the next clinical trial with PrimECC in Q3 and a larger trial in the heart indication in early 2019.
Read more and download the research update: https://goo.gl/6z1rNq
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/